Category - Executive Moves

Executive Moves

BioTime appoints Stephana Patton as general counsel

BioTime (NYSE MKT:BTX) has appointed Stephana Patton as general counsel, a newly created position. Reporting in her new role to Adi Mohanty, co-CEO, Dr. Patton will oversee all legal matters at the company.

February 7, 2017

Executive Moves

Richard Glickman adds CEO title at Aurinia

Richard Glickman, founder and chairman of Aurinia Pharmaceuticals (NASDAQ:AUPH; TSX:AUP), was named to the added post of CEO. The board also accepted the resignation of Charles Rowland as CEO and an executive member of...

February 7, 2017

Executive Moves

Hugh Rogers joins RepliCel board

RepliCel Life Sciences (OTCQB:REPCF; TSX-V:RP) appointed Hugh Rogers to its board.

February 6, 2017

Executive Moves

Kenneth Galbraith joins Profound Medical board

Kenneth Galbraith, an accomplished life sciences industry veteran, has been appointed a director of Profound Medical (TSX-V:PRN). Mr. Galbraith has over 25 years of experience as an executive, director, investor and...

January 18, 2017

Executive Moves

Profound Medical COO joins XOR-Labs board

Steven Plymale, president and COO of Profound Medical (TSX-V:PRN), has been appointed an independent director of XOR-Labs, a spinoff from Toronto General Hospital at University Health Network, the world's leading center...

January 17, 2017

Executive Moves

HCW names John Chambers president, head investment banking

John Chambers has joined H.C. Wainwright as president and head of investment banking. Mr. Chambers joins HCW from Roth Capital Partners where he was vice chairman and head of healthcare investment banking. In his 28...

January 9, 2017

Executive Moves

Roth names Margolis to head healthcare investment banking

Roth Capital Partners has appointed Michael Margolis as head of healthcare investment banking. Mr. Margolis has been a managing director at the firm since 2010.

January 7, 2017

Executive Moves

3DS names Joost van der Mark as CBO

3D Signatures (TSX-V:DXD) has appointed Joost van der Mark as its chief business officer, effective Jan. 6.

January 6, 2017

Executive Moves

Joseph Pantginis joins Rodman

Joseph Pantginis has joined Rodman & Renshaw in equity research as a managing director covering biotechnology.

January 5, 2017

Executive Moves

Titan Pharma adds two members to BOD

Titan Pharmaceuticals (NASDAQ:TTNP), in a move to boost its product development and commercialization experience in the U.S., Europe and Asia, named Scott Smith and Dr. Rajinder Kumar to its board.

January 4, 2017

Category - Executive Moves

General

More